NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 215 filers reported holding NEVRO CORP in Q4 2021. The put-call ratio across all filers is 1.68 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $1,168,000 | -28.0% | 10,036 | +2.5% | 0.01% | -25.0% |
| Q2 2021 | $1,623,000 | +19.5% | 9,790 | +0.5% | 0.01% | +14.3% |
| Q1 2021 | $1,358,000 | -16.3% | 9,738 | +3.9% | 0.01% | -12.5% |
| Q4 2020 | $1,622,000 | +1348.2% | 9,370 | +659.9% | 0.01% | +300.0% |
| Q3 2017 | $112,000 | +24.4% | 1,233 | +2.2% | 0.00% | +100.0% |
| Q2 2017 | $90,000 | -99.4% | 1,207 | -99.2% | 0.00% | -99.6% |
| Q1 2017 | $14,931,000 | +31668.1% | 159,354 | +24799.1% | 0.25% | +25100.0% |
| Q4 2016 | $47,000 | -92.1% | 640 | -92.8% | 0.00% | -90.0% |
| Q4 2015 | $597,000 | +4.0% | 8,843 | -28.6% | 0.01% | +11.1% |
| Q3 2015 | $574,000 | -35.5% | 12,377 | -25.3% | 0.01% | -25.0% |
| Q2 2015 | $890,000 | -20.7% | 16,567 | -29.2% | 0.01% | -25.0% |
| Q1 2015 | $1,122,000 | +13.8% | 23,404 | -8.2% | 0.02% | +6.7% |
| Q4 2014 | $986,000 | – | 25,508 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tiger Eye Capital LLC | 239,122 | $41,392,000 | 8.25% |
| Integral Health Asset Management, LLC | 88,000 | $15,233,000 | 4.53% |
| Iron Triangle Partners LP | 168,761 | $29,213,000 | 3.79% |
| Eos Focused Equity Management, L.P. | 14,002 | $2,424,000 | 2.37% |
| PFM Health Sciences, LP | 311,940 | $53,997,000 | 1.90% |
| Perceptive Advisors | 977,565 | $169,217,000 | 1.82% |
| Rock Springs Capital Management LP | 395,000 | $68,375,000 | 1.45% |
| Lisanti Capital Growth, LLC | 54,302 | $9,400,000 | 1.30% |
| HealthCor Management, L.P. | 156,046 | $27,012,000 | 1.04% |
| FRED ALGER MANAGEMENT, LLC | 2,136,612 | $369,848,000 | 0.96% |